Advertisement

Diabetologia

, Volume 39, Issue 5, pp 587–593 | Cite as

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria

  • The Microalbuminuria Captopril Study Group
Originals

Summary

In insulin-dependent diabetes mellitus (IDDM), microalbuminuria predicts renal and cardiovascular disease. We report a combined analysis of 235 normotensive IDDM patients with microalbuminuria who participated in two 24-month double-blind, randomised, placebo-controlled trials to assess the effects of captopril 50 mg twice daily on the progression to overt clinical albuminuria. Of the 225 patients who were evaluable on an intent to treat basis, 25 of 114 placebo-treated patients (21.9%) and 8 of 111 captopril-treated patients (7.2%) progressed to persistent clinical albuminuria. The risk of progression over 24 months was significantly reduced by captopril (p=0.004) with a risk reduction of 69.2% (95% confidence interval (CI): 31.7 to 86.1%). This degree of risk reduction remained at the same level (62.9% [16.1–83.6%], p=0.017) after adjustment for differences in time-varying mean arterial blood pressure. Albumin excretion rate increased by an average of 14.2% [3.1–26.5%] per year in the placebo-treated group compared with a reduction of 9.6% [−18.6–0.4%] per year in the captopril-treated group (p=0.002). The rate of fall of creatinine clearance tended to be faster in the placebo-treated group than in the captopril-treated group (−6.4 [−10.2–−2.5] vs −1.4 [−5.3–2.6] ml · min−1 · 1.73 m−2, p=0.07). Baseline albumin excretion rate (p<0.0001) and glycated haemoglobin (p=0.03) were independent predictors of progression to clinical albuminuria and changes in mean arterial blood pressure (p=0.02) and serum cholesterol level (p=0.003) were significantly associated with percentage changes in albumin excretion rate. Captopril reduces the risk of progression to overt nephropathy in IDDM patients with microalbuminuria, an effect partly independent of its blood pressure-lowering effects.

Keywords

Microalbuminuria diabetic nephropathy angiotensin converting enzyme inhibition insulin-dependent diabetes mellitus 

Abbreviations

ACE

Angiotensin converting enzyme

IDDM

insulin-dependent diabetes mellitus

GFR

glomerular filtration rate

C

captopril

P

placebo

AER

albumin excretion rate

MAP

mean arterial pressure

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685–689Google Scholar
  2. 2.
    Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294: 1443–1447Google Scholar
  3. 3.
    Parving HH, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ 297: 1086–1091Google Scholar
  4. 4.
    Parving HH, Hommel E, Nielsen MD, Giese J (1989) Effect of captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy. BMJ 299: 533–536Google Scholar
  5. 5.
    Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925–1930Google Scholar
  6. 6.
    Anderson S, Rennke HG, Garcia DL, Brenner BM (1989) Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36: 526–536Google Scholar
  7. 7.
    Bjorck S, Mulec H, Johnsen SA, Nordén G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304: 339–343Google Scholar
  8. 8.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462Google Scholar
  9. 9.
    Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet i:1430–1432Google Scholar
  10. 10.
    Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR (1982) Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 100: 550–555Google Scholar
  11. 11.
    Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89–93Google Scholar
  12. 12.
    Mathiesen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T (1984) Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 26: 406–410Google Scholar
  13. 13.
    Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC (1992) Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus. Kidney Int 41: 836–839Google Scholar
  14. 14.
    Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P (1988) Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 297: 1092–1095Google Scholar
  15. 15.
    Melbourne Diabetic Nephropathy Study Group (1991) Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 302: 210–216Google Scholar
  16. 16.
    Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M (1993) Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin-dependent diabetes. BMJ 306: 175–182Google Scholar
  17. 17.
    Mathiesen ER, Hommel E, Giese J, Parving HH (1991) Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. BMJ 303: 81–87Google Scholar
  18. 18.
    Viberti GC, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group (1994) Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271: 275–279Google Scholar
  19. 19.
    Laffel L, Gans DJ, McGill JB, on behalf of the Captopril Nephropathy Study Group (1993) Captopril decreases the rate of progression of renal disease in normotensive, insulin-dependent diabetes mellitus (IDDM) patients with microalbuminuria. J Am Soc Nephrol 4: 304 (Abstract)Google Scholar
  20. 20.
    Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE (1993) Is screening and intervention for microalbuminuria worthwhile in patients with insulin-dependent diabetes? BMJ 306: 1722–1725Google Scholar
  21. 21.
    Kearney EM, Mount JN, Watts GF, Slavin BM, Kind PRN (1987) Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyzer. J Clin Pathol 40: 465–468Google Scholar
  22. 22.
    Stein EA (1986) Lipids, lipoproteins and apolipoproteins. In: Tietz NW (ed) Textbook of clinical chemistry. WB Saunders, Philadelphia, pp 829–900Google Scholar
  23. 23.
    SAS Institute Inc (1991) SAS Technical Report p 217 “SAS/STAT Software: the PHREG Procedure, Version 6”, SAS Institute Inc, Cary, NCGoogle Scholar
  24. 24.
    SAS Institute Inc (1990) SAS/STAT user's guide, Version 6, 4th edn, SAS Institute, Cary, NCGoogle Scholar
  25. 25.
    SAS Institute Inc (1992) The MIXED Procedure. In: SAS Technical Report p 229, “SAS/STAT Software: Changes and Enchancements, Release 6.07”. SAS Institute Inc, Cary, NC, pp 287–366Google Scholar
  26. 26.
    Wiedmann P, Boehlen LM, de Courten M (1993) Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 8: 582–584Google Scholar
  27. 27.
    Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Int Med 118: 129–138Google Scholar
  28. 28.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 118: 577–581Google Scholar
  29. 29.
    Rossing P, Hommel E, Smidt UM, Parving HH (1994) Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45:S145-S149Google Scholar
  30. 30.
    Apperloo AJ, De Zeeuw D, De Jong PE (1994) Short-term anti-proteinuric response to anti-hypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45:S174-S178Google Scholar
  31. 31.
    Williams JD, Coles GA (1994) Proteinuria — a direct cause of renal morbidity. Kidney Int 45: 443–450Google Scholar
  32. 32.
    Microalbuminuria Collaborative Study Group, UK (1993) Risk factors for the development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 306: 1235–1239Google Scholar
  33. 33.
    Krolewski AS, Warram JH, Christlieb AR (1994) Hypercholesterolemia — a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 45:S125-S131Google Scholar
  34. 34.
    Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T (1991) Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34: 164–170Google Scholar
  35. 35.
    The Diabetes Control and Complications Trial Research Group (1993) The effects of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes. N Engl J Med 329: 977–986Google Scholar
  36. 36.
    Poulsen PL, Hansen KW, Mogensen CE (1994) Ambulatory blood pressure monitoring in the transition from normo- to microalbuminuria. Diabetes 43: 1248–1253Google Scholar
  37. 37.
    Anderson S, Meyer T, Rennke HG, Brenner BM (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612–619Google Scholar
  38. 38.
    Raij L, Keane WF (1985) Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 79[Suppl C]: 24–30Google Scholar
  39. 39.
    Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I (1989) Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36: 626–635Google Scholar
  40. 40.
    Raij L, Luscher TF, Vanhoutte PM (1988) High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension 12: 562–567Google Scholar
  41. 41.
    The Microalbuminuria Collaborative Study Group, UK (1995) Intensive therapy and progression to clinical albuminuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. BMJ 311: 973–977Google Scholar
  42. 42.
    Diabetes Control and Complications (DCCT) Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 42: 1703–1720Google Scholar
  43. 43.
    Siegel JE, Krolewski AS, Warram JH, Weinstein WC (1992) Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 3: 3111–3119Google Scholar
  44. 44.
    Robdy R, Firth L, Lewis E (1994) An economic analysis of captopril in the treatment of diabetic nephropathy. J Am Soc Nephrol 5: 382 (Abstract)Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • The Microalbuminuria Captopril Study Group

There are no affiliations available

Personalised recommendations